What is replacing tirzepatide? Weight-loss medicines in Phase 3 in 2026

Is retatrutide replacing tirzepatide?

No. Research does not show that retatrutide replaces tirzepatide. TRIUMPH-5 compares them directly in adults with obesity. ClinicalTrials.gov lists this study as NCT06662383. Its status is Phase 3 and active, not recruiting, checked 17 October 2026. This means the study is still running, but new people cannot join. It does not mean medical care has changed. A direct test can answer a set question about one group. Any reported difference needs a closer look. Unwanted effects, missing data and who took part all matter. A trial name alone cannot settle a treatment choice.

Start with the compound already being discussed. What is tirzepatide? explains the trial record behind that name. Comparing two medicines and replacing one with another are separate questions.

Which hormone receptors are these compounds designed to target?

These compounds target different sets of receptors. Receptors are proteins that receive chemical messages called hormones. GLP-1 stands for glucagon-like peptide-1. This gut hormone plays a part in blood sugar and hunger signals. GIP stands for glucose-dependent insulinotropic polypeptide. This gut hormone plays a part in insulin release. Insulin is a hormone that controls blood sugar. Glucagon tells the liver to release stored sugar. Amylin is a hormone released with insulin after food. Retatrutide acts at GLP-1, GIP and glucagon receptors. Jastreboff and colleagues describe this in the New England Journal of Medicine in 2023. A target map shows how a compound is meant to work. It cannot predict the full result in people.

CagriSema combines two compounds. Cagrilintide activates amylin receptors, while semaglutide activates GLP-1 receptors. Survodutide targets GLP-1 and glucagon receptors. VK2735 targets GLP-1 and GIP receptors. Maker statements dated 7 June 2026 give the targets for CagriSema and survodutide. The VK2735 maker statement is dated 29 July 2026. Counting targets cannot tell you a compound's value in medical care.

Which obesity and diabetes medicines have Phase 3 programmes in 2026?

Retatrutide, CagriSema, survodutide and VK2735 have Phase 3 studies. The records were checked 17 October 2026. The table lists each name, its targets and a study record. ClinicalTrials.gov records show whether a study is still running or has ended. Retatrutide's TRANSCEND-T2D-1 diabetes trial, NCT06354660, is completed. TRIUMPH-5 is still active at this check. One research programme can have both kinds of study. These examples cover obesity or type 2 diabetes. They do not list every medicine being studied. The same compound may have other studies that ask quite different questions.

CagriSema's maker statement of 7 June 2026 names two programmes. REDEFINE looks at weight management. REIMAGINE looks at type 2 diabetes. The VK2735 statement of 29 July 2026 names VANQUISH-1 and VANQUISH-2. Both programme descriptions were checked 17 October 2026.

Survodutide's SYNCHRONIZE-START record was first posted on 2 October 2026. The separate diabetes study NCT07754461 had an update posted on 14 October 2026. Both are Phase 3 records on ClinicalTrials.gov, checked 17 October 2026. These are dates for the records. They do not predict when results will arrive.

Does Phase 3 mean a medicine is ready to replace an existing treatment?

No. Phase 3 names a stage of tests in people. It does not give permission to replace a treatment. The trial record has separate fields for phase, recruitment and results. Recruitment means signing up people for a study. Not yet recruiting means this has not started. Active, not recruiting means a study runs on but is closed to new people. Completed means it has ended. That label alone does not tell you what the study found. These ClinicalTrials.gov entries show the differences, checked 17 October 2026. A maker's summary needs its own date and source too. A reported result is separate from a decision by health authorities.

How long has retatrutide been studied? explains the timeline. Always read a result with the programme's name beside it. One study's findings cannot stand in for all studies of that compound.

Can trial headlines show which new medicine works better?

No. Headlines alone cannot show which medicine works better in all settings. Studies need to ask the same question to be compared. They need a suitable group to compare results against. They also need a clear account of unwanted effects. Jastreboff and colleagues reported a retatrutide trial in 2023. It compared retatrutide with a placebo, which has no active compound. That paper does not compare retatrutide directly with tirzepatide. Who took part and how long they were tracked matter. So does the way missing results are handled. Placing numbers from separate studies side by side does not remove these differences. It cannot show which medicine ranks highest in all settings.

Names can be confusing too. This guide to compound and medicine names explains the difference. It also separates the questions their trials ask.

Evidence limits

What can this Phase 3 list not show?

A separate page asks What is the status of the retatrutide TRIUMPH-OUTCOMES trial?. Check that record on its own terms. Research material is not an approved medicine or a substitute for prescribed treatment. It is not for human or animal use.